全文获取类型
收费全文 | 373篇 |
免费 | 28篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 29篇 |
妇产科学 | 3篇 |
基础医学 | 35篇 |
口腔科学 | 30篇 |
临床医学 | 43篇 |
内科学 | 74篇 |
皮肤病学 | 5篇 |
神经病学 | 16篇 |
特种医学 | 61篇 |
外科学 | 28篇 |
综合类 | 28篇 |
预防医学 | 23篇 |
药学 | 6篇 |
中国医学 | 4篇 |
肿瘤学 | 20篇 |
出版年
2021年 | 9篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 6篇 |
2016年 | 6篇 |
2015年 | 9篇 |
2014年 | 6篇 |
2013年 | 17篇 |
2012年 | 17篇 |
2011年 | 15篇 |
2010年 | 26篇 |
2009年 | 12篇 |
2008年 | 12篇 |
2007年 | 7篇 |
2006年 | 10篇 |
2005年 | 8篇 |
2004年 | 6篇 |
2003年 | 3篇 |
2002年 | 4篇 |
2001年 | 2篇 |
2000年 | 7篇 |
1999年 | 4篇 |
1998年 | 23篇 |
1997年 | 14篇 |
1996年 | 19篇 |
1995年 | 8篇 |
1994年 | 14篇 |
1993年 | 9篇 |
1992年 | 6篇 |
1991年 | 8篇 |
1990年 | 5篇 |
1989年 | 12篇 |
1988年 | 13篇 |
1987年 | 16篇 |
1986年 | 10篇 |
1985年 | 6篇 |
1984年 | 8篇 |
1983年 | 3篇 |
1982年 | 8篇 |
1981年 | 2篇 |
1980年 | 5篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1976年 | 7篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1971年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有406条查询结果,搜索用时 15 毫秒
11.
A. H. V. Schapira P. Barone R. A. Hauser Y. Mizuno O. Rascol M. Busse C. Debieuvre M. Fraessdorf W. Poewe for the Pramipexole ER Studies Group 《European journal of neurology》2013,20(1):50-56
Background and purpose: In chronic diseases including Parkinson’s disease (PD), complex pharmacotherapy dosing schedules are reported to reduce adherence, perhaps leading to less‐effective symptom control and, in PD, more erratic stimulation of dopamine receptors. However, blinded clinical‐trial designs preclude direct comparisons of adherence to various schedules. Methods: In two double‐blind (DB) studies of early PD and one of advanced PD, subjects received three‐times‐daily (t.i.d.) pramipexole or placebo. In open‐label (OL) extensions, subjects took extended‐release, once‐daily (q.d.) pramipexole. At 24 or 32 OL weeks, q.d. versus t.i.d. dosing preference was surveyed by questionnaire. Results: Of 590 DB‐trial completers with early PD, 511 entered the OL extension. Of 374 survey respondents, 94.4% preferred q.d. dosing (72.2% of them found it ‘very much more convenient’ and 27.8%‘more convenient’), 2.7% preferred t.i.d., and 2.9% chose ‘no difference’. Of 465 DB‐trial completers with advanced PD, 391 entered its OL extension. Of 334 survey respondents, 88.9% preferred q.d. dosing (59.9% of them found it ‘very much more convenient’ and 40.1%‘more convenient’), 5.7% preferred t.i.d., and 5.4% chose ‘no difference’. Results excluding DB‐placebo recipients were highly similar. Conclusions: In this first direct comparison of patient preference for q.d. versus t.i.d. dopamine‐agonist dosing, patients with early or advanced PD had a strong preference for q.d. rather than t.i.d. pramipexole. The high proportion of advanced‐PD patients declaring this preference indicates that it does not depend on whether a patient is taking concomitant PD medications dosed more frequently than q.d. 相似文献
12.
13.
Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4- one iron chelators in overloaded and nonoverloaded mice 总被引:3,自引:1,他引:3
Five orally effective iron chelators of the 3-hydroxypyridin-4-one series have been administered intraperitoneally to iron-overloaded and nonoverloaded male mice at a dose of 200 mg/kg/24 h for a total of 60 days to investigate the effect on iron loading and toxicity. There was a significant reduction in hepatic iron at the end of the study in the iron-overloaded mice with all compounds studied using chemical iron quantitation (P less than .001) and with Perls' stain (P less than .01). Liver iron removal with the hydroxypyridinones ranged from 37% with CP20 to 63% with CP51, compared with 46% removal for desferrioxamine (DFO). There was no significant reduction in splenic or cardiac iron with any chelator. There were no deaths in iron-overloaded animals receiving any of the hydroxypyridin-4-ones, but significantly more deaths in the nonoverloaded groups as a whole (P less than .03). No weight loss was observed with any chelator. Significant reductions in hemoglobin and white cell count were observed with CP20(L1). No histologic abnormalities of kidney, spleen, bone marrow, or stifle joints were observed. Intracytoplasmic inclusion bodies were observed in the centrilobular hepatocytes of animals administered each of the hydroxypyridin-4-ones, while the DFO-treated and control groups showed no such changes. 相似文献
14.
Aaron A Phillips Darren ER Warburton Philip N Ainslie Andrei V Krassioukov 《Journal of cerebral blood flow and metabolism》2014,34(5):794-801
Individuals with high-level spinal cord injury (SCI) experience low blood pressure (BP) and cognitive impairments. Such dysfunction may be mediated in part by impaired neurovascular coupling (NVC) (i.e., cerebral blood flow responses to neurologic demand). Ten individuals with SCI >T6 spinal segment, and 10 age- and sex-matched controls were assessed for beat-by-beat BP, as well as middle and posterior cerebral artery blood flow velocity (MCAv, PCAv) in response to a NVC test. Tests were repeated in SCI after 10 mg midodrine (alpha1-agonist). Verbal fluency was measured before and after midodrine in SCI, and in the control group as an index of cognitive function. At rest, mean BP was lower in SCI (70±10 versus 92±14 mm Hg; P<0.05); however, PCAv conductance was higher (0.56±0.13 versus 0.39±0.15 cm/second/mm Hg; P<0.05). Controls exhibited a 20% increase in PCAv during cognition; however, the response in SCI was completely absent (P<0.01). When BP was increased with midodrine, NVC was improved 70% in SCI, which was reflected by a 13% improved cognitive function (P<0.05). Improvements in BP were related to improved cognitive function in those with SCI (r2=0.52; P<0.05). Impaired NVC, secondary to low BP, may partially mediate reduced cognitive function in individuals with high-level SCI. 相似文献
15.
目的:了解进展较快的食管和贲门癌前病变的时间,为寻找合适的筛查间隔提供线索.方法:在食管癌高发区河北涉县对40~69岁人群开展重复的内镜筛查.结果:301例重复筛查共观察到40例病情发生进展者,其中7例重度不典型增生中:1例首检为正常,间隔13个月检出重度不典型增生,1例首检为基底细胞增生,间隔7个月检出,4例首检为轻度不典型增生,分别间隔3个月、4个月、4个月、10.5个月检出,1例首检为中度不典型增生,间隔12.5个月检出;6例原位癌及黏膜内癌中:1例首检为轻度不典型增生,间隔48个月检出,2例中度不典型增生分别间隔4个月、13个月检出2例,3例重度不典型增生分别间隔3.5个月、9个月、17.5个月检出;3例浸润性癌中:1例中度不典型增生,间隔50个月检出、2例重度不典型增生间隔14个月和19个月检出.结论:食管和贲门癌前病变的滞留时间变异较大,有必要适当缩短筛查间隔,通过及时复查捕获那些进展较快、多点起源和首检遗漏的癌前病变. 相似文献
16.
17.
18.
目的研究复苏因子蛋白对休眠结核杆菌的复苏作用,探索对休眠结核杆菌的最佳复苏方案。方法应用含不同浓度复苏因子蛋白的7H9液体培养基培养休眠结核杆菌H37Rv,分别在第6天、第11天、第16天、第30天检测培养物的OD值、并取10μL培养液涂于7H11平板培养、抗酸染色。结果低浓度组合有最佳复苏效果,高浓度复苏因子组合抑制体眠结核菌复苏。低浓度复苏因子A和高、低浓度的复苏因子B、C、E均有不同程度的复苏促进作用,复苏因子D和高浓度的复苏因子A均无复苏作用。重复试验结果相同。结论结核杆菌复苏因子蛋白对结核杆菌有复苏促进作用。 相似文献
19.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
20.
Metin OZKAN Bulent ESER Ozlem ER H. Senol COSKUN Ahmet OZTURK Ismail SARI Ozlem CANOZ Mustafa ALTINBAS 《Asia-Pacific Journal of Clinical Oncology》2006,2(1):32-38
The more metastatic sites and bone marrow metastasis in small cell lung cancer (SCLC), the worse the prognosis. Diagnosing the bone marrow invasion at the beginning of the therapy is important for determining of the prognosis and planning the treatment. Abnormalities of some blood parameters may help to estimate the extent of bone marrow invasion by cancer cells. In this retrospective review, the changes in routine laboratory tests that may indicate bone marrow invasion, the predictive values of these tests, and the prognostic importance of bone marrow invasion were evaluated in SCLC patients who were being followed up according to a protocol. One hundred and forty‐four patients with SCLC were enrolled in this study. Retrospectively, it was evaluated that 25 (17.4%) of the patients had bone marrow metastasis. According to univariate analysis, there was a significant difference between hemoglobin, white blood cell count, platelet count, lactate dehydrogenase, alkaline phosphatase and uric acid of the patients with and without bone marrow involvement. Among the biochemical parameters, the elevated LDH and AP had the highest sensitivity and specificity as indicators of bone marrow invasion (0.80–0.82 and 0.84–0.78, respectively). The median overall survival of extensive‐stage disease with and without bone marrow metastasis were 4.0 ± 1.0 months (95% CI 2.2–5.7) and 7.0 ± 1.2 months (95% CI 4.7–9.3), respectively (P = 0.03). Bone marrow metastasis was found to be an indicator of a bad prognosis. Bone marrow biopsy, that is an invasive procedure, can be performed on selected patients who have changes of routine laboratory tests suggesting bone marrow invasion. 相似文献